{"title": "PDF", "author": "PDF", "url": "https://inversionistas.medicasur.com.mx/site/uploads/es/documents/general_documents/medicasur_press_release_2T22.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Resultados  no auditados 2T22 \n \n1 \n \n \n2T21 2T22 Var ($) Var (%) 2021 2022 $ Var % Var\nIngresos 928.5 983.3 54.8 5.9% 1,868.7 1,951.6 82.9 4.4%\nUtilidad de Operaci\u00f3n 180.3 168.0 (12.2)    -6.8% 420.9 333.0 (87.9)     -20.9%\nMargen de Operaci\u00f3n 19.4% 17.1% -2.3 pp 22.5% 17.1% -5.5 pp\nEBITDA* 381.0 703.7 322.7 84.7% 859.1 960.7 101.6 11.8%\nMargen EBITDA* 41.0% 71.6% 30.5 pp 46.0% 49.2% 3.3 pp\nUtilidad Neta Consolidada* 191.4 500.6 309.3 161.6% 458.3 663.0 204.7 44.7%\nMargen Neto* 20.6% 50.9% 30.3 pp 24.5% 34.0% 9.4 pp\nCifras en millones de pesos, incluye efectos de redondeo.\n* Cifras con efectos de operaciones discontinuadasM\u00e9dica Sur, S.A.B. de C.V. y Subsidiarias\nResultados no auditados\nAcumulado TrimestralCiudad  de M\u00e9xico, a 22 de julio de 2022 \u2013 MEDICA , S.A.B. de C.V.  (\u201cMedica Sur\u201d, \u201cM EDICA \u201d, \u201cMS\u201d, la  \u201cCompa\u00f1\u00eda \u201d) (Clave de \ncotizaci\u00f3n BMV: M EDICA B y CEBURES MEDICA 20 ) reporta sus resultados  no auditados  correspondientes al segundo \ntrimestre del 202 2 (2T22). Esta informaci\u00f3n se presenta de acuerdo con  las Normas Internacionales de Informaci\u00f3n \nFinanciera ( IFRS, por sus siglas en ingl\u00e9s) . \n\u258b M\u00e9dica Sur reporta incrementos de 85% en EBITDA y 162% en Utilidad Neta del \n2T22 en comparaci\u00f3n con el 2T21. \n\u2022 M\u00e9dica Sur continua  con resultados favorables derivados de la mayor demanda de servicios core que han compensado \nel descenso en ingresos por servicios COVID .  \n \n\u2022 Los ingresos del segundo  trimestre d e 2022 sumaron $983.3 millones de pesos, c recieron 5.9% comparados con el \nmismo periodo del a\u00f1o anterior, y a nivel acumulado  alcanzaron $1,951.6 millones, 4.4% m\u00e1s que el primer semestre \nde 2021.  \n \n\u2022 La utilidad de operaci\u00f3n fue de $168.0 millones,  con un margen operativo del 17.1%. Tuvo un descenso de 6.8% en \ncomparaci\u00f3n con el 2T21  que se debi\u00f3 principalmente a una menor contribuci\u00f3n de las ventas COVID  respecto al \nmismo periodo de 2021, ya que la utilidad de operaci\u00f3n del negocio core  increment\u00f3 en forma importante no obstante \nel mayor gasto por PTU  derivado de  la reforma laboral .  \n \nA nivel acumulado, la utilidad de operaci\u00f3n del primer semestre de 2022 sum\u00f3 $333.0 millones , disminuy\u00f3  20.9% \ncontra el mismo periodo del a\u00f1o anterior y tuvo un margen  de 17. 1%. El descenso se explica por los puntos descritos \nen el p\u00e1rrafo anterior.   \n \n\u2022 El EBITDA  de la compa\u00f1\u00eda durante el 2T22 fue de $703.7 millones, tuvo un incremento de 84.7 % en  comparaci\u00f3n con \nel mismo periodo del a\u00f1o anterior  y un margen de 71.6%. Lo anterior incluye efectos por operaciones discontinuadas \npor $493.0 millones . \n \nA nivel acumulad o, el EBITDA del primer semestre  de 2022  sum \u00f3 $960.7 millones , un aumento del 11.8% contra el \nmismo periodo del a\u00f1o anterior  y un margen del 49.2%. Lo anterior incluye efectos por operaciones discontinuadas  \npor $539.6 millones.  \n \n\u2022 La Utilidad Neta  del segundo trimestre  de 2022  sum\u00f3 $500.6 millones, creci\u00f3 161.6% comparado con el 2T21 y tuvo  \nun margen neto de 50.9%.  Lo anterior incluye efectos de operaciones discontinuadas por $356.1 millones.  \n \nA nivel acumulado,  la Utilidad Neta  alcanz\u00f3 $663.0 millones, aument \u00f3 44.7% y tuvo un margen neto de 34 .0%. Lo \nanterior incluye efectos de operaciones discontinuadas por $3 85.8 millones.  \n \n\u2022 La Caja  finaliz\u00f3 el segundo trimestre en $3, 698.5  millones, lo cual genera una deuda neta negativa de $ 2,698.5 \nmillones.  \n  \n \n \n \n \n \n Resultados  no auditados 2T22 \n \n2 \n \n \u258b Volumen e indicadores Hospital 2T22 \n\u2022 Durante el 2T22 , Medica Sur cont\u00f3 con la confianza de 3,650  pacientes egresados de hospitalizaci\u00f3n , un incremento \ndel 16% respecto del mismo periodo del ejercicio anterior.  \n\u2022 Durante el 2T22  la estancia media de pacientes hospitalizados descendi\u00f3 ligeramente al pasar de  4.19  a 3.39  d\u00edas, lo \nque significa que los pacientes tuvieron una estancia 19.1 % menor  en comparaci\u00f3n con el segundo  trimestre del \n2021.  \n\u2022 El porcentaje de ocupaci\u00f3n del 2T22 fue de 67.8%, pr\u00e1cticamente el mismo que durante 2T21 que fue de 68%.  \n \nEventos impo rtantes 2T22:  \n \n\u258b M\u00e9dica Sur y Mayo Clinic extienden su relaci\u00f3n para incluir atenci\u00f3n en c\u00e1ncer de \nmama.  \nM\u00e9dica Sur es miembro de la Mayo Clinic Care Network  desde 2013,  fue el primer hospital fuera de los Estados Unidos \ny primer hospital en el mundo en ser parte de la red que tiene como respaldo el prestigio de la Cl\u00ednica Mayo.  M\u00e9dica \nSur y Cl\u00ednica Mayo trabajan en conjunto compartiendo los mismos valores y priorizando las n ecesidades del paciente \nsobre todas las cosas. Esta colaboraci\u00f3n es un beneficio que se traduce en el bienestar de cada uno de los pacientes y \nnos sentimos orgullosos y satisfechos de esta alianza.   \nEsta relaci\u00f3n se fortalece con la colaboraci\u00f3n extendida que inicialmente se centrar\u00e1 en homologar protocolos para el \ntratamiento de padecimientos oncol\u00f3gicos,  incluidos el diagn\u00f3stico y el tratamiento  e iremos adicionando las diferentes \nespecialidades m\u00e9dicas que atendemos dentro del hospital.  \nMayo Clinic Care Network es una plataforma en la que los m\u00e9dicos pueden consultar entre sus colegas dudas puntuales \ne informarse sobre avances de \u00faltimo momento  en procedimientos de salud. La Red tambi\u00e9n tiene una dimensi\u00f3n \nacad\u00e9mica, en la que, a\u00f1o con a\u00f1o, intercambiamos experiencias  e informaci\u00f3n sobre casos concretos entre altos \nespecialistas, y contribuye a la actualizaci\u00f3n m\u00e9dica.   \n \n \n \n \nResultados  no auditados 2T22 \n \n3 \n \n \u2022 Atenci\u00f3n COVID  \nA lo largo de la pandemia hemos atendido  m\u00e1s de 3,400 pacientes en hospitalizaci\u00f3n  por COVID -19. \nSi bien durante el primer trimestre de 2022 reconvertimos el piso que ten\u00edamos destinado para la atenci\u00f3n de \npacientes COVID, contamos con la flexibilidad de reh abilitarlo en caso de un nuevo repunte o si la contingencia \nsanitaria  lo requiere, as\u00ed como la posibilidad de habilitar ubicaciones de Toma de muestras de laboratorio en la \nmodalidad de Autoexpress para comodidad de nuestros pacientes como sucedi\u00f3 en el se gundo trimestre  con el \nrepunte de la quinta ola de contagios por la que atraviesa la Ciudad de M\u00e9xico.  \n \nResumen Financiero 2T22 \n\u2022 Ingresos   \nLos ingresos del segundo trimestre del 2022 sumaron $983.3 millones de pesos, crecieron 5.9% comparados con \nel mismo periodo del a\u00f1o anterior, y a nivel acumulado alcanzaron $1,951.6 millones, 4.4% m\u00e1s que el primer \nsemestre de 2021 . Observamos crecimientos importantes en nuestras  tres principales actividades:  \nHospital  \nDurante el 2T22, Medica Sur cont\u00f3 con la conf ianza de 3,650 pacientes egresados de hospitalizaci\u00f3n , un \nincremento del 16% respecto del mismo periodo del ejercicio anterior.  \n \nLos ingresos por servicios no COVID contribuyeron $74 millones m\u00e1s que el mismo trimestre del a\u00f1o anterior:  \nel volumen de cirug\u00edas creci\u00f3 13% , la atenci\u00f3n en unidades cr\u00edticas creci\u00f3 40% y los pacientes de urgencia s 22% \nm\u00e1s.   \n \nEste crecimiento se vio compensado por el descenso en hospitalizaci\u00f3n cr\u00edtica y no cr\u00edtica relacionada con \nCOVID -19 por $104  millones menos, comparado  con el 2T21. Dando como resultado un decremento neto de \n$30 millones en este segmento.    \n \nServicios Cl\u00ednicos y Unidades de Diagn\u00f3stico  \nEsta unidad de negocio contribuy\u00f3 con $ 58 millones de pesos m\u00e1s que el a\u00f1o anterior, observando un aumento \nrelevante en la demanda de servicios como:  \n- Centro Oncol\u00f3gico, que realiz\u00f3 26% quimioterapias m\u00e1s . \n- Radiocirug\u00eda Gamma Knife realiz\u00f3 75% m\u00e1s procedimientos .  \n- Resonancia Magn\u00e9tica realiz\u00f3 13% m\u00e1s estudios .  \n- PET-CT increment\u00f3  11%.  \n- Angiograf\u00eda realiz\u00f3 7% m\u00e1s estudios.  \n- Gastroenterolog\u00eda realiz\u00f3 5% m\u00e1s estudios.  \n- Imagenolog\u00eda creci\u00f3 2%.  \n- Urolog\u00eda Avanzada increment \u00f3 14% . \n \nOtros  \nEste segmento  creci\u00f3 $ 26.7  millones comparado con el mismo periodo del a\u00f1o anterior , impulsado por:  \n- Una mayor afluencia de visitantes a las concesiones de cafeter\u00edas y restaurantes.  \n- Increment\u00f3 la ocupaci\u00f3n del hotel Holiday Inn.  \n- Mayores ventas en Farmacia.  \n- Aumentaron los ingresos por renta de consultorios.   \n Resultados  no auditados 2T22 \n \n4 \n \n  \nGr\u00e1fico de ingresos  \nCifras en millones de pesos  \n\u2022 Utilidad de Operaci\u00f3n   \nLa utilidad de operaci\u00f3n fue de $168.0 millones, con un margen operativo del 17.1%. Tuvo un descenso de 6.8% en \ncom parac i\u00f3n con el 2T21 que se debi\u00f3 principalmente  a una menor contribuci\u00f3n  de las ventas COVID  respecto al \nmismo periodo de 2021, ya que la utilidad de operaci\u00f3n del negocio  core  increment\u00f3 en forma importante no \nobstante el mayor gas to por PTU derivado de la reforma laboral . \n \nA nivel acumulado, la utilidad de operaci\u00f3n del primer semestre de 2022 sum\u00f3 $333.0 millones, disminuy\u00f3 20.9% \ncontra el mismo periodo del a\u00f1o anterior y tuvo un margen de 17. 1%. El descenso se explica por los puntos descritos \nen el p\u00e1rrafo anterior.  \n \n \n \n \n\u2022 Operaciones  Discontinuadas  \nDurante el primer semestre del 2022, la Emisora recibi\u00f3 $593  millones de grupo SYNLAB International GmbH \n(Synlab) , compuestos por : \n- $385 millones relacionad os con  la venta del negocio de Laboratorio M\u00e9dico Polanco en cumplimiento con las \ncondiciones variables acordadas para el ejercicio 2022  que incluyen regal\u00edas  por las ventas  COVID . \n- $208 millones provenientes de la venta de 20 sucursales bajo la marca Laboratorios M\u00e9dica Sur  concretada  \nen abril de 2022.  \n- Despu\u00e9s de gastos e impuestos, e l efecto neto de las operaciones discontinuadas es de $385.8 millones  en el \nprimer semestre del 2022 .  \n \nPara mayor detalle respecto a  las Operaciones discontinuadas, se puede consultar la secci\u00f3n \u201c[800500] \noperaciones discontinuadas \u201d de este reporte.  \nIngresos (mdp)\n928.5983.3\n2T21 2T225.9%\n1,868.71,951.6\n2021 20224.4%\n180.3 168.0\n2T21 2T22420.9\n333.0\n2021 2022-20.9%\n-6.8%\nMargen de operaci\u00f3n\n17.1%19.4 %22.5%\n17.1%\nGr\u00e1fico de utilidad de operaci\u00f3n.  \nCifras en millones de pesos  \n \n Resultados  no auditados 2T22 \n \n5 \n \n \u2022 EBITDA  \nEl EBITDA  de la compa\u00f1\u00eda durante el 2T22 fue de $703.7 millones, tuvo un incremento de 84.7% en comparaci\u00f3n con \nel mismo periodo del a\u00f1o anterior y un margen de 71.6%. Lo anterior incluye efectos por operaciones discontinuadas \npor $493.0 millones.  \n \nA nivel acumulad o, el EBITDA del primer semestre de 2022  sum \u00f3 $960.7 millones , un aumento del 11.8% contra el \nmismo periodo del a\u00f1o anterior  y un margen del 49.2%. Lo anterior incluye efectos por operaciones discontinuadas  \npor $539.6 millones.  \n \nGr\u00e1fico EBITDA,  incluye efectos de operaciones discontinuadas  \nCifras en millones de pesos  \n\u2022 Impuestos  \nLos impuest os del 2T22 fueron 1.0% mayores en comparaci\u00f3n con el mismo periodo del ejercicio anterior, ya que se \nobtuvo una mayor utilidad.  \nPara consultar los efectos fiscales de la operaci\u00f3n discontinuada consultar la Lista de notas en la secci\u00f3n 800500  de \neste reporte.   \n \n\u2022 Costo Integral de Financiamiento (CIF)  \nEl CIF del trimestre registr\u00f3 un efecto favorable  al situarse en $ 41 millones de pesos. Lo anterior se explica por un \naumento relevante en los intereses ganados, derivado de una mayor caja por l os ingresos recibidos  por la venta del \nnegocio LMP  y mayores tasas de inter\u00e9s.  \n \n \n \n \n \n* EBITDA = Utilidad de operaci\u00f3n m\u00e1s amortizaci\u00f3n y depreciaci\u00f3n, Incluye efectos de IFRS16\nCifras en mdp381.0703.7\n2T21 2T2284.7%\n859.1960.7\n2021 202211.8%\n71.6%\nMargen EBITDA41.0%\n46.0%49.2%\nCifras en millones de pesos 2T21 2T22 \u0394 a/a  $ \u0394 a/a  %\nUtilidad (p\u00e9rdida) cambiaria (3.1)                    1.0                     4.1                     -131.9%\nIntereses Pagados (20.2)                  (18.9)                 1.3                     -6.2%\nIntereses Ganados 4.3                      58.9                   54.6                   1268.5%\nCIF (19.0)                 41.0                  60.0                  -316%Resultados  no auditados 2T22 \n \n6 \n \n \u2022 Utilidad Neta  \nLa Utilidad Neta del segundo trimestre de 2022 sum\u00f3 $500.6 millones, creci\u00f3 161.6% comparado con el 2T21 y tuvo \nun margen neto de 50.9%. Lo anterior incluye efectos de operaciones discontinuadas por $356.1 millones.  \n \nA nivel acumulado, la Utilidad Neta alcanz\u00f3 $663.0 millones, aument\u00f3 44.7% y tuvo un margen neto de 34 .0%. Lo \nanterior incluye efectos de operaciones discontinuadas por $385.8 millones.   \n \n \nGr\u00e1fico de utilidad neta, incluye efectos de operaciones discontinuadas  \nCifras en millones de pesos  \n\u2022 Deuda  \nLa deuda total del grupo es de $1,000 millones de pesos a trav\u00e9s de la emisi\u00f3n del Certificado Burs\u00e1til MEDICA20, a \nuna tasa fija del 6.99% anual, con pago de intereses semestral y vencimiento en septiembre de 2025. La compa\u00f1\u00eda \nse mantiene al corriente en el pago de sus obligaciones.  \n \n \n \n \n \n \n \n\u2022 Fondo de Recompra   \n \nDurante el segundo trimestre del a\u00f1o , la Emisora realiz\u00f3 operaciones del fondo de recompra por un total de 974 mil \nacciones e invirti\u00f3 $50 millones de pesos . \n \nAl 30 de junio de 2022 , la compa\u00f1\u00eda ha comprado 1 4.9 millones de acciones con un valor total de $ 446.2 millones de \npesos a un costo promedio por acci\u00f3n de $2 9.98  pesos , equivalente a una tenencia accionaria de 12.1 %. \nEl valor de mercado al 30 de junio de 2022 es de $806 millones.  \nEl saldo en la reserva de acciones es de $ 450.4  millones de peso s.  \n191.4500.6\n2T21 2T22458.3663.0\n2021 2022161.6%\n50.9%\n20.6%\nMargen neto\n24.5%34.0%\n44.7%\nAPALANCAMIENTO  \n-1.3x  \nCAJA 2T22  \n$3,699  \n+5% vs 2T21  \nCifras en millones de pesos 2T21 2T22 \u0394 a/a  $ \u0394 a/a  %\nDeuda con costo 1,000     1,000     -         -\nEfectivo 3,532     3,699     167        5%\nDeuda neta (2,532)   (2,699)  \nApalancamiento -1.4x -1.3x\n(Deuda Neta / EBITDA LTM)Resultados  no auditados 2T22 \n \n7 \n \n Anexos Financieros (no auditados) (cifras en pesos)  \nM\u00e9dica Sur, S.A.B. de C.V.  \nEstado de Situaci\u00f3n Financiera al 31 de diciembre de  2021 y 30 de junio de 2022. \n \n \n3Cierre 2021 2T22 Cambio % a/a Cambio $ a/a\nActivo Total 6,984,041,098 7,189,264,781 2.9% 205,223,683\nActivos circulantes 4,133,124,027 4,366,887,155 5.7% 233,763,128\nEfectivo e Inversiones Temporales 3,531,821,699 3,698,546,963 4.7% 166,725,264\nClientes y Documentos por cobrar (Neto)\u00a0\u00a0 448,098,049 479,847,839 7.1% 31,749,790\nOtras Cuentas y Documentos por Cobrar \n(Neto)26,427,581 37,863,754 43.3% 11,436,173\nInventarios\u00a0\u00a0 126,776,699 150,628,599 18.8% 23,851,901\nInmuebles, Planta y Equipo (Neto) 2,578,385,612 2,552,249,378 -1.0% -26,136,234\nInmueble 2,934,576,637 2,957,754,663 0.8% 23,178,026\nMaquinaria y Equipo Industrial 56,343,457 57,597,414 2.2% 1,253,956\nOtros Equipos 937,662,055 935,434,458 -0.2% -2,227,596\nActivo por Derecho de Uso 97,636,784 72,486,732 -25.8% -25,150,053\nDepreciaci\u00f3n Acumulada -1,480,659,933 -1,532,178,448 3.5% -51,518,515\nDepreciaci\u00f3n Acum Activo por derecho de uso -33,957,774 -23,509,867 -30.8% 10,447,907\nConstrucciones en Proceso 66,784,386 84,664,426 26.8% 17,880,041\nPropiedades de inversi\u00f3n 73,424,493 70,628,523 -3.8% -2,795,969\nTerreno 52,165,613 52,165,613 0.0% 0\nEdificio 21,258,879 18,462,910 -13.2% -2,795,969\nActivos Intangibles Neto 199,106,966 199,499,724 0.2% 392,758\nPasivo Total 2,069,742,793 1,982,760,004 -4.2% -86,982,789\nPasivo Circulante 1,003,843,425 925,721,223 -7.8% -78,122,202\nProveedores 269,143,231 302,696,051 12.5% 33,552,819\nCr\u00e9ditos Bursatiles 19,416,667 19,416,667 0.0% 0\nImpuestos por Pagar\u00a0\u00a0 338,845,135 161,669,756 -52.3% -177,175,379\nOtros Pasivos Circulantes 354,258,128 425,958,028 20.2% 71,699,900\nPasivos por arrendamiento a CP 22,180,264 15,980,721 -28.0% -6,199,543\nPasivo a Largo Plazo 1,065,899,368 1,057,038,781 -0.8% -8,860,587\nCr\u00e9ditos Bursatiles 991,928,321 993,010,467 0.1% 1,082,147\nOtros Cr\u00e9ditos 30,968,955 30,502,805 -1.5% -466,150\nPasivos por arrendamiento a LP 43,002,092 33,525,508 -22.0% -9,476,583\nCapital Contable 4,914,298,304 5,206,504,777 5.9% 292,206,474\nParticipaci\u00f3n No Controladora 955,639 955,639 0.0% 0\nCapital Contable Atribuible a la Participaci\u00f3n \nControladora4,913,342,665 5,205,549,138 5.9% 292,206,474\nCapital Social\u00a0Pagado 517,873,932 517,873,932 0.0% 0\nPrima en Venta de Acciones 121,280,931 121,280,931 0.0% 0\nAportaciones para Futuros Aumentos de \nCapital124,628 124,628 0.0% 0\nResultados Acumulados y Reserva de Capital 2,705,744,785 3,461,546,710 27.9% 755,801,925\nReserva para Recompra de Acciones 422,517,711 450,400,721 6.6% 27,883,009\nResultado Neto del Ejercicio 1,154,516,740 663,005,688 -42.6% -491,511,052\nOtras Partidas de Resultado Integral -8,716,064 -8,683,473 -0.4% 32,591\nCapital Contable y Pasivo 6,984,041,096 7,189,264,781 2.9% 205,223,685\nCifras bajo IFRSResultados  no auditados 2T22 \n \n8 \n \n Anexos Financieros (no auditados) ( cifras en pesos)  \nM\u00e9dica Sur, S.A.B. de C.V.  \nEstados de Resultados del segundo  trimestre de 202 1 y 202 2. \n \n \n \n \n \nToda la informaci\u00f3n financiera presentada en este reporte fue preparada de acuerdo con  las Normas Internacionales de Informaci\u00f3n \nFinanciera (IFRS, por sus siglas en ingl\u00e9s . \n \n \n \n2T21 2T22 Cambio % a/a Cambio P$ a/a\nIngresos\u00a0\u00a0 928,494,426 983,256,969 5.9% 54,762,544\nCosto de ventas\u00a0\u00a0 -568,140,810 -623,730,215 9.8% -55,589,404\nUtilidad bruta\u00a0\u00a0 360,353,615 359,526,755 -0.2% -826,861\n0\nGastos de Venta\u00a0y Administraci\u00f3n -179,900,345 -185,561,875 3.1% -5,661,530\nOtros Gastos de Operaci\u00f3n -187,824 -5,930,548 3057.5% -5,742,724\nUtilidad (p\u00e9rdida) de operaci\u00f3n\u00a0\u00a0 180,265,446 168,034,331 -6.8% -12,231,115\n0\nUtilidad (Perdida) Cambiaria -3,127,981 998,553 -131.9% 4,126,534\nIntereses Pagados -20,187,821 -18,937,813 -6.2% 1,250,007\nIntereses Ganados 4,306,034 58,927,275 1268.5% 54,621,241\nUtilidad (p\u00e9rdida) antes de Impuestos 161,255,678 209,022,346 29.6% 47,766,668\nImpuestos a la Utilidad -51,706,205 -64,440,806 24.6% -12,734,601\nUtilidad (p\u00e9rdida) por Operaciones \nContinuas109,549,473 144,581,539 32.0% 35,032,066\nUtilidad de Operaciones Discontinuadas, \nneto81,823,519 356,062,861 335% 274,239,342\nUtilidad (p\u00e9rdida) neta consolidada del a\u00f1o 191,372,992 500,644,400 161.6% 309,271,408\n0\nParticipaci\u00f3n no Controladora -37,941 0 -100.0% 37,941\nParticipaci\u00f3n Controladora 191,335,052 500,644,400 161.7% 309,309,348\nCifras bajo IFRSResultados  no auditados 2T22 \n \n9 \n \n Anexos Financieros (no auditados) (cifras en pesos)  \nM\u00e9dica Sur, S.A.B. de C.V.  \nEstados de Resultados de  enero a junio de 2021 y 2022.  \n \n \n \n \nToda la informaci\u00f3n financiera presentada en este reporte fue preparada de acuerdo con las Normas Internacionales de Informaci\u00f3n \nFinanciera (IFRS, por sus siglas en ingl\u00e9s . \n \n \n \nA JUNIO 2021 A JUNIO 2022 Cambio % a/a Cambio P$ a/a\nIngresos\u00a0\u00a0 1,868,738,987 1,951,605,459 4.4% 82,866,472\nCosto de ventas\u00a0\u00a0 -1,118,708,521 -1,235,103,021 10.4% -116,394,500\nUtilidad bruta\u00a0\u00a0 750,030,466 716,502,438 -4.5% -33,528,028\n0\nGastos de Venta\u00a0y Administraci\u00f3n -329,854,497 -386,187,660 17.1% -56,333,163\nOtros Gastos de Operaci\u00f3n 730,309 2,675,642 266.4% 1,945,333\nUtilidad (p\u00e9rdida) de operaci\u00f3n\u00a0\u00a0 420,906,278 332,990,420 -20.9% -87,915,858\n0\nUtilidad (Perdida) Cambiaria -21,796 -1,666,705 7547.0% -1,644,909\nIntereses Pagados -39,047,697 -37,814,163 -3.2% 1,233,534\nIntereses Ganados 9,181,693 108,067,697 1077.0% 98,886,004\nUtilidad (p\u00e9rdida) antes de Impuestos 391,018,479 401,577,250 2.7% 10,558,772\nImpuestos a la Utilidad -123,040,865 -124,398,325 1.1% -1,357,460\nUtilidad (p\u00e9rdida) por Operaciones \nContinuas267,977,613 277,178,925 3.4% 9,201,312\nUtilidad de Operaciones Discontinuadas, \nneto190,319,564 385,826,763 103% 195,507,199\nUtilidad (p\u00e9rdida) neta consolidada del a\u00f1o 458,297,177 663,005,688 44.7% 204,708,511\n0\nParticipaci\u00f3n no Controladora -8,915 0 -100.0% 8,915\nParticipaci\u00f3n Controladora 458,288,262 663,005,688 44.7% 204,717,426\nCifras bajo IFRSResultados  no auditados 2T22 \n \n10 \n \n Cobertura de Analistas  \nDe acuerdo con  lo establecido por el reglamento interior de la BMV en el art\u00edculo 4.033.01 fracc. VIII en materia de \nrequisitos de mantenimiento, informamos que la Casa de Bolsa que da cobertura de an\u00e1lisis a nuestros valores es \nGrupo Burs\u00e1til Mexicano S.A. de C.V., Cas a de Bolsa y Miranda Global Research  como analista independiente.  \n \nAcerca de MEDICA  \nMEDICA, S.A.B. de C.V. (BMV: MEDICAB) es un operador de hospitales y un proveedor integrado de servicios del \ncuidado de la salud y servicios relacionados. Provee estos serv icios a trav\u00e9s de hospitales y laboratorios. En MEDICA \nse re\u00fane a un grupo de m\u00e9dicos, profesionales de la medicina, enfermer\u00eda, administraci\u00f3n y operaci\u00f3n hospitalaria y \nse tiene como objetivo ofrecer un servicio de excelencia m\u00e9dica con calidez humana gu iado por un estricto c\u00f3digo de \n\u00e9tica y respaldado por equipos e infraestructura m\u00e9dica con tecnolog\u00eda de vanguardia.  \n \nEBITDA*  \nEl EBITDA es un indicador utilizado en el an\u00e1lisis financiero de la Compa\u00f1\u00eda que no se reconoce en las IFRS pero que se \ncalcula a partir de las cifras derivadas de los estados financieros de la Compa\u00f1\u00eda . Las siglas EBITDA  se refieren a las \nutilidades antes de ingresos financieros, impuestos, depreciaci\u00f3n y amortizaci\u00f3n y equivalen a Earnings Before Interest, \nTaxes, Depreciation and Amortization . \nPara las cifras de 202 1 y 202 2; el EBITDA Incluye los efectos de la norma contable de arrendamientos IFRS16 . \nEl EBITDA no es indicador financiero bajo IFRS, tampoco es un indicador sobre liquidez o rendimiento, consideramos \nque el EBITDA puede ser \u00fatil para facilitar las comparaciones del desempe\u00f1o operativo entre per\u00edodos en una base \ncombinada, pero otros emisores pueden calcular estas m\u00e9tricas de manera di ferente.  \nEl EBITDA no debe interpretarse como una alternativa a (i) la utilidad neta como un indicador del desempe\u00f1o operativo \nde la Compa\u00f1\u00eda o (ii) el flujo de efectivo de las actividades operativas como una medida de la liquidez de la Compa\u00f1\u00eda.  \n \nDeclara ciones a Futuro  \nEste informe contiene declaraciones respecto al futuro. Dichas declaraciones incluyen, de manera enunciativa pero no limitati va: (i) \ndeclaraciones en cuanto a nuestra situaci\u00f3n financiera y resultados de operaci\u00f3n; (ii) declaraciones en cuanto a nuestros planes, objetivos o \nmetas, incluyendo declaraciones en cuanto a nuestras actividades; y (iii) declaraciones en cuanto a las presunciones subyacen tes en que se basan \ndichas declaraciones. Las declaraciones respecto al futu ro contienen palabras tales como \u201cpretende\u201d, \u201cprev\u00e9\u201d, \u201cconsidera\u201d, \u201cestima\u201d, \u201cespera\u201d, \n\u201cpronostica\u201d, \u201cplanea\u201d, \u201cpredice\u201d, \u201cbusca\u201d, \u201cpodr\u00eda\u201d, \u201cdeber\u00eda\u201d, \u201cposible\u201d, \u201clineamiento\u201d y otros vocablos similares, ya sea en primera o Cuarta \npersona, sin embargo, no  son los \u00fanicos t\u00e9rminos utilizados para identificar dichas declaraciones.  \nPor su propia naturaleza, las declaraciones respecto al futuro conllevan riesgos e incertidumbres de car\u00e1cter tanto general c omo espec\u00edfico y \nexiste el riesgo de que no se cumplan l as predicciones, los pron\u00f3sticos, las proyecciones y las dem\u00e1s declaraciones respecto al futuro. Se advierte \na los inversionistas que hay muchos factores importantes que pueden ocasionar que los resultados reales difieran sustancialme nte de los \nexpresados en los planes, objetivos, expectativas, estimaciones y afirmaciones tanto expresas como impl\u00edcitas contenidas en las declarac iones \ncon respecto al futuro.  \nLa informaci\u00f3n relacionada con el desempe\u00f1o futuro contenida en este press release debe leerse conju ntamente con los riesgos incluidos en la \nsecci\u00f3n \u201cFactores de riesgo\u201d presentado ante la Comisi\u00f3n Nacional de Bancar\u00eda y Valores (CNBV).  \n \n \nCONTACTO\nRelaci\u00f3n con Inversionistas :    Arely Guti\u00e9rrez\nTel: 52(55) 5424 7200  Ext. 3425   agutierrezg@medicasur.org.mx\nUnaudited results  2Q22 \n \n1 \n \n \n2Q21 2Q22 Var ($) Var (%) 2021 2022 Var ($) Var (%)\nRevenues 928.5 983.3 54.8 5.9% 1,868.7 1,951.6 82.9 4.4%\nOperating income 180.3 168.0 (12.2)    -6.8% 420.9 333.0 (87.9)     -20.9%\nOperating margin 19.4% 17.1% -2.3 pp 22.5% 17.1% -5.5 pp\nEBITDA* 381.0 703.7 322.7 84.7% 859.1 960.7 101.6 11.8%\nEBITDA* margin 41.0% 71.6% 30.5 pp 46.0% 49.2% 3.3 pp\nConsolidated net income* 191.4 500.6 309.3 161.6% 458.3 663.0 204.7 44.7%\nNet margin* 20.6% 50.9% 30.3 pp 24.5% 34.0% 9.4 pp\nFigures expressed in millions of Mexican pesos, including rounding effects.\n* Figures including the effects of discontinued operations.M\u00e9dica Sur, S.A.B. de C.V. and Subsidiaries\nUnaudited results\nQuarterly AccumulatedMexico City, July 22, 2022 - MEDICA, S.A.B. de C.V. (\"M \u00e9dica Sur\", \"MEDICA\", or the \"Company\") (BMV ticker symbol s: \nMEDICAB and CEBURES MEDICA 20) reports its unaudited results for the second quarter of 2022 (2Q22). This \ninformation is presented in accordance with International Financial Reporting Standards (IFRS).  \n\u258b M\u00e9dica Sur reported increased EBITDA by 85% and Net Income by 162% in 2Q22 \ncompared to the same quarter of the previous year.  \n\u2022 M\u00e9dica Sur experienced strong results driven by increased demand for core services, which offset the decrease \nobserved in revenues from COVID services.   \n \n\u2022 M\u00e9dica Sur's revenues for the second quarter of 2022 totaled Ps. 983.3 million, representing an increase of 5.9% in \ncomparison with the same period of the previous year. On a cumulative basis, the Company's revenues reached Ps. \n1,951.6 million, 4.4% higher than the figure recorded in the first six months of the previous year.  \n \n\u2022 Operating income  for the quarter was Ps. 168.0 million, with an  operating margin of 17.1%. Operating income \nexperienced a decrease of 6.8% in comparison with the same quarter of 2021, primarily because of  a lower \ncontribution from COVID sales compared to the previous year 's quarter. Notably, core business operating income grew \nsignificantly despite the recognition of higher employee profit sharing (an effect of Mexico's labor reform).  \n \nOperating income for the first half of 2022 was Ps. 333.0 million, a 20.9% decrease in c omparison to the same period \nof 2021 . The operating margin was 17.1%. These adjustments are mainly due to the effects mentioned above.  \n \n\u2022 The Company's EBITDA for 2Q22 was Ps. 703.7 million, an expansion of 84.7% compared to the same period of the \nprevious year, while the EBITDA margin was 71.6%. This includes the effects of discontinued operations in the amount \nof Ps. 493.0 million.  \n \nFor the first half of 2022, EBITDA stood at Ps. 960.7 million, an increase of 11.8% in comparison with the figure fo r the \nsame period of the previous year. The cumulative EBITDA margin was 49.2%. The foregoing reflects discontinued \noperations of Ps. 539.6 million.  \n \n\u2022 The Company's Net Income  for the second quarter of 2022  reached Ps. 500.6 million , considering the effect of \ndiscontinued operations of Ps. 356.1 million,. This represented an increase of 161.6% compared to the figure for the \nsecond quarter of the previous year. The net margin was 50.9%.  \n \nFor the first six months of the year, net incom e reached Ps. 663.0 million, an increase of 44.7%, while net margin was \n34.0%. This includes the effects of discontinued operations of Ps. 385.8 million.  \n \n\u2022 At the end of the second quarter of , 2022 , MEDICA's cash position was Ps. 3,698.5 million, which resulted in a net debt \nof Ps. 2,698.5 million.  \n \n \n \n \n \n \n \n Unaudited results  2Q22 \n \n2 \n \n \u258b Hospital metrics in 2Q22  \n\u2022 During the second quarter of 2022, Medica Sur recorded 3,650 patients discharged to home , an increase of 16% in \ncomparison with the same period of the previous fiscal year.  \n\u2022 The average inpatient stay in the period decreased slightly from 4.19 to 3.39 days, which means  patients had a 19.1% \nshorter stay compared to the second quarter of 2021. The occupancy rate stood at 67.8% during the quarter, \npractically the same level recorded in the previous year's quarter, which was 68%.  \n \nKey events during 2Q22:  \n \n\u258b M\u00e9dica Sur and Mayo Clinic extend their relationship  to include breast cancer \ncare  \nM\u00e9dica Sur has been a member of the Mayo Clinic Care Network since 2013. M\u00e9dica Sur was the first non -US hospital \nand the first medical center to join the network, which is backed by the prestige of the Mayo Clinic. Our company  and \nMayo Clinic are work ing together sharing the same values and prioritizing the needs of patients. This collaboration \ntranslates into the well -being of each of our patients . We are proud and honored to be  a part of this alliance.  \nThis relationship is strengthened by the extended co llaboration that will initially focus on standardizing protocols for the \ntreatment of oncological conditions, including diagnosis and treatment, and we will gradually add the different medical \nspecialties that we serve within the hospital.  Mayo  Clinic Care Network is a platform where doctors can consult with \ncolleagues about specific matters  and inquire about the latest advances in health procedures. The Network also has an \nacademic dimension, in which, year after year, we exchange experiences a nd information on specific cases among high ly \nskilled medical teams  and contribute to medical updating.  \n \n \n\u2022 COVID patient care  \nThroughout the pandemic , we have treated more than 3,400 patients hospitalized for COVID -19.The hospital floor \nfor COVID attention was reconverted in the first quarter of 2022, leaving the Company with the flexibility to enable \nit again if the pandemic should experience a new out break, or in the event that the health contingency should require  \nso. Aside from the above, MEDICA could re-enable  locations for taking laboratory samples (Autoexpress modality for \nthe convenience of patients), in the event of a resurgence of COVID -19 infections, as occurred  in Mexico City during \nthe second quarter due to the outbreak of the fifth wave of the pandemic.  \nUnaudited results  2Q22 \n \n3 \n \n 2Q22 Financial Summary  \n \n\u2022 Revenues  \nRevenues for the second quarter of 2022 totaled Ps. 983.3 million, an increase of 5.9% in comparison with the same \nperiod of the previous year. For the first six months of the year, the Company's revenues were Ps. 1,951.6 million, \n4.4% higher than the figu re recorded in the first half of the previous year. MEDICA reported revenue growth in each \nof its three main business areas:  \nHospital  \nIn the second quarter of the year, Medica Sur registered 3,650 patients released from hospitalization, an \nincrease of 16%  in comparison to the same period of the previous year.  \n \nRevenues from non -COVID services contributed an additional Ps. 74 million to the figure reported in the same \nquarter of the previous year, in which the number of surgeries increased by 13%, critical care units expanded \n40%, and emergency room patients increased 22%.   \n \nThese variations were offset by lower activity in critical and non -critical hospitalization related to COVID -19, \nleading to adjustments of Ps. 104 million when compared to  the second quarter of the previous year. This \nreflected a net reduction of Ps. 30 million in this segment.  \n \nClinical and Diagnostic Units  \n During the quarter, this business unit contributed an additional Ps. 58 million to 2022 revenues compared to \nthe pri or-year period, mainly as a result of higher demand for services in:  \n \n\u25aa Oncology Center (+26% chemotherapies).  \n\u25aa Gamma Knife Radiosurgery (+75% in procedures performed).  \n\u25aa Magnetic Resonance Imaging (+13% in studies performed).  \n\u25aa PET-CT increased by 11%  .  \n\u25aa Angiography (+7% studies).  \n\u25aa Gastroenterology (+5% studies ).  \n\u25aa Imaging grew 2% .  \n\u25aa Advanced Urology (+14%).  \n \nOther \nWhen compared to the prior -year quarter, this segment's revenues increased Ps. 26.7 million, mainly as a result \nof: \n \n\u25aa A higher visitors' inflow to the cafeteria and restaurant concessions.  \n\u25aa Higher occupancy rate at the Holiday Inn hotel.  \n\u25aa Higher sales at the Pharmacy.  \n\u25aa Growth in income from medical office rentals.  \n \n Unaudited results  2Q22 \n \n4 \n \n  \nRevenues  \nFigures in millions of pesos  \n \n\u2022 Operating income  \nOperating income for the second quarter of the year was Ps. 168.0 million, resulting in an operating margin of 17.1%. \nThe decrease of 6.8% compared to the same period of the previous year resulted from a lower contribution of COVID \nsales compared to the sa me period of 2021. Core business operating income expanded significantly despite  the \nrecognition of higher expenses related to workers' profit sharing (a result of the labor reform in Mexico).  \n \nOn a cumulative basis, operating income for the first six months of 2022 totaled Ps. 333.0 million, a decrease of \n20.9% in comparison with the same period of the previous year. The Company's operating margin was 17.1%. These \nresults are mainly due to the e ffects previously explained.  \n \n \n \nOperating income  \nFigures in millions of pesos  \n \n\u2022 Discontinued operations  \nIn the first half of 2022, the Company benefited from proceeds of Ps. 593 million from SYNLAB International GmbH \n(Synlab) group, which are comprised as follows:  \n \n\u25aa Ps. 385 million related to the sale of the Laboratorio M\u00e9dico Polanco business in accordance with \nthe variable portion agreed to in 2022, including royalties on COVID sales from this transaction.  \n\u25aa Ps. 208 million from the sale of 20 branches under the Laboratorios M\u00e9dica Sur brand, which was \ncompleted in April 2022.  \n\u25aa The net effect of discontinued operations in the first six months of 2022, after payment and \nprovisions for expenses and taxes, is Ps.  385.8 million.  \n \n928.5983.3\n2Q21 2Q225.9%\n1,868.71,951.6\n2021 20224.4%\n180.3 168.0\n2Q21 2Q22420.9\n333.0\n2021 2022-20.9%\n-6.8%\nOperating Margin\n17.1%19.4 % 22.5%\n17.1%\nUnaudited results  2Q22 \n \n5 \n \n Readers are referred to the \"[800500] discontinued operations\" section of this report for further details regarding \nthe Company's discontinued operations.  \n \n\u2022 EBITDA  \nThe Company's EBITDA totaled Ps. 703.7 million in the second quarter of 2022, an increase of 84.7% in comparison \nwith the figure recorded in the same quarter of the previous year. EBITDA margin for the quarter was 71.6%. These \ninclude the effect of discont inued operations  in the amount of Ps. 493 .0 million.  \nOn a cumulative basis, the Company's EBITDA totaled Ps. 960.7 million, representing an increase of 11.8% when \ncompared to the same period of the previous year, resulting in an EBITDA margin of 49.2%. Thi s includes effects from \ndiscontinued operations in the amount of Ps. 539.6 million.  \n \n \nEBITDA, including effects of discontinued operations  \nFigures in millions of pesos  \n\u2022 Taxes  \nHigher pre -tax income in the quarter resulted in a 1.0% increase in tax provisions in respect to the same period of \nthe previous year.  \n \nReaders are refer red to Section 800500 of this report concerning the tax effects of discontinued operations . \n \n\u2022 Comprehensive Cost of Financing (CCF) \nCCF for the second quarter of the year reflected a Ps. 41 million positive effect as a result of a significant increase in \ninterest gains, driven by a higher cash position obtained from the sale of the Laboratorio M\u00e9dic o Polanco business  \nand higher interest rates.  \n \n \n \n381.0703.7\n2Q21 2Q2284.7%\n859.1960.7\n2021 202211.8%\n71.6%\nEBITDA Margin41.0%\n46.0%49.2%\nFigures in million pesos 2Q21 2Q22 Var ($) Var (%)\nForeign exchange profit (loss) (3.1)        1.0         4.1     -131.9%\nInterest expenses (20.2)     (18.9)     1.3     -6.2%\nInterest income 4.3         58.9       54.6  1268.5%\nComprehensive Cost of Financing (19.0)     41.0      60.0  -316%Unaudited results  2Q22 \n \n6 \n \n \u2022 Net income  \nNet Income for the second quarter of 2022 stood at Ps. 500.6 million, 161.6% higher than the figure recorded in the \nsecond quarter of the previous year, resulting in a net margin of 50.9%. The above includes the recognition of \ndiscontinued operations for Ps. 356.1 million.  \n \nOn a cumulative basis, net income was Ps. 663.0 million, 44.7% higher than the figure for the same period of the \nprevious year.  Net margin was 34.0%. This includes the effects of discontinued operations of Ps. 385.8 million.  \n \n \n \nNet income, including effects of discontinued operations  \nAmounts in millions of pesos  \n \n\u2022 Intere st-bearing debt  \nAs of June 30, 2022, the Company's total interest -bearing debt was Ps. 1,000.0 million, composed  of the issuance of \nthe debt certificates ( Certificado Burs\u00e1til ) MEDICA20. This instrument, which matures in September 2025, pays a \nfixed annual interest rate of 6.99%, with interest payable semiannually. To date, t he Company has complied \nsatisfactorily with its debt commitments.  \n \n \n  \n \n\u2022 Stock Repurchase Fund  \n \nIn the second quarter of the year, the Company completed stock repurchase fund transactions for a total of 974 \nthousand shares, which represented transactions of Ps. 50 million.  \n \nAs of June 30, 2022, the company has acquired 14.9 million shares with a total value of Ps. 446.2 million at an average \ncost per share of Ps. 29.98, equivalent to a 12.1% shar eholding. The market value is Ps. 806 million, while the balance \nin the share reserve is valued at Ps. 450.4 million.  \n \n \n191.4500.6\n2Q21 2Q22458.3663.0\n2021 2022161.6%\n50.9%\n20.6%\nNet Margin \n24.5%34.0%\n44.7%\nFigures in million pesos 2Q21 2Q22 Var ($) Var (%)\nInterest-bearing debt 1,000     1,000     -    -\nCash 3,532     3,699     167    5%\nNet Debt (2,532)  (2,699)  \nLeverage -1.4x -1.3x\n(Net Debt / EBITDA LTM)\nLEVERAGE  \n-1.3x  \nCASH POSITION 2 Q22 \nPs. 3,699  \n+5% vs 2 Q21 Unaudited results  2Q22 \n \n7 \n \n Financial Statements ( unaudited) (amounts in Mexican pesos)  \nM\u00e9dica Sur, S.A.B. de C.V.  \nBalance Sheet as of December 31, 2021 and June 3 0, 2022 . \n \n2021 2Q22 Change % YoY Change $ YoY\nAssets 6,984,041,098 7,189,264,781 2.9% 205,223,683\nCurrent assests 4,133,124,027 4,366,887,155 5.7% 233,763,128\nCash and Cash Equivalents 3,531,821,699 3,698,546,963 4.7% 166,725,264\nAccounts Receivable 448,098,049 479,847,839 7.1% 31,749,790\nOthers Net Account Receivable 26,427,581 37,863,754 43.3% 11,436,173\nInventories 126,776,699 150,628,599 18.8% 23,851,901\nProperty, Plant and Equipment (Net) 2,578,385,612 2,552,249,378 -1.0% -26,136,234\nProperty 2,934,576,637 2,957,754,663 0.8% 23,178,026\nIndustrial Machinery and Equipment 56,343,457 57,597,414 2.2% 1,253,956\nOther Equipment 937,662,055 935,434,458 -0.2% -2,227,596\nRight-of-use asset 97,636,784 72,486,732 -25.8% -25,150,053\nAccumulated Depreciation -1,480,659,933 -1,532,178,448 3.5% -51,518,515\nAccumulated Depreciation Right-of-use asset -33,957,774 -23,509,867 -30.8% 10,447,907\nConstructions in Process 66,784,386 84,664,426 26.8% 17,880,041\nInvestment properties 73,424,493 70,628,523 -3.8% -2,795,969\nLand 52,165,613 52,165,613 0.0% 0\nBuildings 21,258,879 18,462,910 -13.2% -2,795,969\nIntangible Assets 199,106,966 199,499,724 0.2% 392,758\nTotal Liabilities 2,069,742,793 1,982,760,004 -4.2% -86,982,789\nCurrent Liabilities 1,003,843,425 925,721,223 -7.8% -78,122,202\nSuppliers 269,143,231 302,696,051 12.5% 33,552,819\nShort-term securities Loans 19,416,667 19,416,667 0.0% 0\nIncome tax payable 338,845,135 161,669,756 -52.3% -177,175,379\nOther Current Liabilities 354,258,128 425,958,028 20.2% 71,699,900\nShort-term lease liability 22,180,264 15,980,721 -28.0% -6,199,543\nLong-term Liabilities 1,065,899,368 1,057,038,781 -0.8% -8,860,587\nBank Loans 0 0 0.0% 0\nAccrued Interest 991,928,321 993,010,467 0.1% 1,082,147\nOther Credits 30,968,955 30,502,805 -1.5% -466,150\nLong-term lease liability 43,002,092 33,525,508 -22.0% -9,476,583\nDeferred Income Taxes 0 0 N/A 0\nOther Liabilities 0 0 N/A 0\nStockholders Equity 4,914,298,304 5,206,504,777 5.9% 292,206,474\nNon-Controlling Interest 955,639 955,639 0.0% 0\nEquity attributable to Equity Holders of the \nCompany 4,913,342,665 5,205,549,138 5.9% 292,206,474\nPaid-in Capital\u00a0Stock 517,873,932 517,873,932 0.0% 0\nPremium in Share Placement 121,280,931 121,280,931 0.0% 0\nContributions for Future Capital Increases 124,628 124,628 0.0% 0\nRetained earnings 2,705,744,785 3,461,546,710 27.9% 755,801,925\nReserve for Share Buyback Program 422,517,711 450,400,721 6.6% 27,883,009\nIncome of the year 1,154,516,740 663,005,688 -42.6% -491,511,052\nOther Comprehensive Income -8,716,064 -8,683,473 -0.4% 32,591\nTotal Liabilities and Shareholders Equity 6,984,041,096 7,189,264,781 2.9% 205,223,685\nAmounts in accordance with IFRSUnaudited results  2Q22 \n \n8 \n \n Financial Statements ( unaudited) (amounts in Mexican pesos)  \nM\u00e9dica Sur, S.A.B. de C.V.  \nIncome Statements of the second quarter of 2021 and 2022  \n \n \n \n \nThe financial information contained in this report was prepared in accordance with International Financial \nReporting Standards (IFRS).  \n \n \n \n \n \n \n2Q21 2Q22 Change % YoY Change $ YoY\nRevenues 928,494,426 983,256,969 5.9% 54,762,544\nCost of Sales -568,140,810 -623,730,215 9.8% -55,589,404\nGross Profit 360,353,615 359,526,755 -0.2% -826,861\n0\nSelling and Administrative Expenses -179,900,345 -185,561,875 3.1% -5,661,530\nOther Operating Expenses -187,824 -5,930,548 3057.5% -5,742,724\nOperating Income 180,265,446 168,034,331 -6.8% -12,231,115\nForeign Exchange Gain (loss) -3,127,981 998,553 -131.9% 4,126,534\nInterest Expense -20,187,821 -18,937,813 -6.2% 1,250,007\nInterest Income 4,306,034 58,927,275 1268.5% 54,621,241\nIncome before Taxes 161,255,678 209,022,346 29.6% 47,766,668\nIncome Tax Expense -51,706,205 -64,440,806 24.6% -12,734,601\n Continuous Operations Profit (loss) 109,549,473 144,581,539 32.0% 35,032,066\nDiscontinued Operations Loss 81,823,519 356,062,861 335.2% 274,239,342\nNet Income 191,372,992 500,644,400 161.6% 309,271,408\nNon-Controlling Income -37,941 0 -100.0% 37,941\nControlling Income 191,335,052 500,644,400 161.7% 309,309,348\nAmounts in accordance with IFRSUnaudited results  2Q22 \n \n9 \n \n Financial Statements ( unaudited) (amounts in Mexican pesos)  \nM\u00e9dica Sur, S.A.B. de C.V.  \nIncome Statements of the first six -month period of 2021 and 2022  \n \n \n \n \nThe financial information contained in this report was prepared in accordance with International Financial \nReporting Standards (IFRS).  \n \n \n \n \n \n \n \n \n \n \n2021 2Q22 Change % YoY Change $ YoY\nRevenues 1,868,738,987 1,951,605,459 4.4% 82,866,472\nCost of Sales -1,118,708,521 -1,235,103,021 10.4% -116,394,500\nGross Profit 750,030,466 716,502,438 -4.5% -33,528,028\nSelling and Administrative Expenses -329,854,497 -386,187,660 17.1% -56,333,163\nOther Operating Expenses 730,309 2,675,642 266.4% 1,945,333\nOperating Income 420,906,278 332,990,420 -20.9% -87,915,858\nForeign Exchange Gain (loss) -21,796 -1,666,705 7547.0% -1,644,909\nInterest Expense -39,047,697 -37,814,163 -3.2% 1,233,534\nInterest Income 9,181,693 108,067,697 1077.0% 98,886,004\nIncome before Taxes 391,018,479 401,577,250 2.7% 10,558,772\nIncome Tax Expense -123,040,865 -124,398,325 1.1% -1,357,460\n Continuous Operations Profit (loss) 267,977,613 277,178,925 3.4% 9,201,312\nDiscontinued Operations Loss 190,319,564 385,826,763 0.0% 195,507,199\nNet Income 458,297,177 663,005,688 44.7% 204,708,511\nNon-Controlling Income -8,915 0 -100.0% 8,915\nControlling Income 458,288,262 663,005,688 44.7% 204,717,426\nAmounts in accordance with IFRSUnaudited results  2Q22 \n \n10 \n \n Coverage by Analysts  \nPer the provisions of the internal regulations of the Mexican Stock Exchange (BMV by its initials in Spanish) outlined in \nsection VIII of article 4.033.01 regarding maintenance requirements, we confirm that the Brokerage House that \nprovides analysis covera ge for our securities is Grupo Burs\u00e1til Mexicano S.A. de C.V., Casa de Bolsa ; Miranda Global \nResearch  is an independent analyst.  \n \nAbout MEDICA  \nMEDICA, S.A.B. de C.V. (NYSE: MEDICAB) is a hospital operator and an integrated provider of health care and relat ed \nservices. It offers these services through hospitals and laboratories. MEDICA brings together a group of physicians, \nmedical professionals, nurses, hospital administration and operations, and aims to offer a service of medical excellence \nwith human touc h guided by a strict code of ethics and supported by state -of-the-art medical equipment and \ninfrastructure.  \n \nEBITDA*  \nEBITDA is an indicator utilized in the financial analysis of the Company that is not recognized by the IFRS but is \ncalculated based on the numbers derived from the Company\u2019s financial statements. We calculate EBITDA as the \noperations revenue plus depreciat ion and amortization.  \nFor the 202 1 and 202 2 numbers, the EBITDA  includes the effects of the IFRS 16 leases accounting standard.   \nEBITDA is not a financial indicator under IFRS, nor is it an indicator of liquidity or performance. We consider that EBITDA \ncan be useful to facilitate comparisons of operating performance between periods on a combined basis, although \nother issuers may calculate these metrics differently.  \nEBITDA must not be interpreted as an alternative to net income as an indicator of the Comp any's operating \nperformance nor to the cash flow from operating activities as a measure of the Company's liquidity.  \n \nForward -looking statements  \nThis report contains forward -looking statements. Such statements include but are not limited to: (i ) statements regarding our financial condition \nand operating results; (ii) statements regarding our plans, objectives, or targets, including statements concerning our activ ities; and (iii) \nstatements regarding the underlying assumptions upon which those st atements are based. Forward -looking statements contain words such as \n\"intends,\" \"anticipates,\" \"considers,\" \"estimates,\" \"expects,\" \"foresees,\" \"plans,\" \"predicts,\" \"seeks,\" \"could,\" should,\u201d \"p ossible,\u201d \u201cguideline,\u201d \nand other similar terms, either in the first or third person. However, these are not the only terms used to identify these statements.  \nBy their very nature, forward -looking statements involve risks and uncertainties of both a general and specific nature, including the risk that such \nprediction s, forecasts, projections, and other forward -looking statements are not  fulfilled. Investors are cautioned that many important factors \nmay cause actual results to differ materially from those expressed in the plans, objectives, expectations, estimates, and  statements, both \nexpressed and implied, contained in the forward -looking statements.  \nThe information related to future performance contained in this press release must be read jointly with the risks included in  the \u201cRisk Factors\u201d \nsection submitted to th e National Banking and Securities Commission (CNBV).   \n", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}